Tribune Therapeutics Raises EUR 37 Million

“LifeArc Ventures is pleased to support Tribune Therapeutics and to lead its Series A financing. Tribune Therapeutics has the opportunity to pioneer a new approach to the treatment of fibrotic diseases that could make debilitating conditions like idiopathic pulmonary fibrosis manageable, improving quality of life and giving new hope to thousands of patients diagnosed each year.”

Chris Baker, PhD, Investment Principal at LifeArc Ventures

Read the release here